FDA al­lows first piv­otal tri­al of an in vi­vo gene edit­ing treat­ment from In­tel­lia

The FDA cleared In­tel­lia Ther­a­peu­tics to run a Phase III study of its CRISPR-based ther­a­py for transthyretin (AT­TR) amy­loi­do­sis with car­diomy­opa­thy, paving the way for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER